Silence Therapeutics reported net income of -$12.27M for the quarter ended Jun 2026. This income statement covers 16 quarters of results from Dec 2018 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2018 | Dec2019 | Dec2020 | Dec2021 | Dec2022 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue & cost | ||||||||||||||||
| Revenue | 15.70M | 0.80M | 1.50M | 25.30M | 0.14M | 0.22M | 0.16M | 0.03M | 0.42M | |||||||
| Cost of RevenueCost of Rev | 2.80M | 3.33M | 3.64M | 2.04M | 0.05M | 0.09M | 0.06M | 0.01M | 0.01M | |||||||
| Gross Profit | 12.90M | -2.58M | -2.14M | 23.27M | 0.09M | 0.14M | 0.10M | 0.02M | 0.41M | |||||||
| Operating items | ||||||||||||||||
| Research & DevelopmentR&D | 11.85M | 13.80M | 20.16M | 22.08M | 20.81M | 17.65M | 20.54M | 8.75M | 9.12M | 9.15M | ||||||
| Selling, General & AdministrativeSG&A | 6.63M | 7.01M | 7.70M | 5.54M | 7.68M | 5.13M | 5.79M | 3.73M | 7.03M | 4.72M | ||||||
| Restructuring CostsRestructuring | 1.32M | |||||||||||||||
| Other Operating ExpensesOther Opex | -21.99M | -24.67M | -28.38M | -20.72M | ||||||||||||
| Operating ExpensesOpex | -3.51M | -3.86M | 27.86M | 27.62M | 0.12M | 3.38M | 26.34M | 12.48M | 16.15M | 13.87M | ||||||
| Operating IncomeOp. Inc | -5.58M | -23.39M | -30.00M | -4.35M | -28.41M | -23.96M | -26.24M | -12.46M | -15.74M | -13.87M | ||||||
| EBIT | -5.58M | -23.39M | -30.00M | -4.35M | -28.41M | -23.96M | -26.24M | -12.46M | -15.74M | -13.87M | ||||||
| Non-operating items | ||||||||||||||||
| Other Non Operating IncomeOther Non Op Inc. | 0.67M | 1.35M | -11.40M | 15.74M | -3.77M | -6.61M | 1.93M | -0.02M | 0.57M | 0.67M | ||||||
| Net income details | ||||||||||||||||
| EBT | -2.07M | -19.53M | -35.49M | 12.63M | -28.53M | -27.34M | -20.96M | -12.85M | -14.96M | -12.27M | ||||||
| Tax ProvisionsTaxes | 0.24M | 0.23M | 0.05M | -11.64M | 0.01M | 0.00M | -22.16M | 0.00M | ||||||||
| Profit After TaxPAT | -2.31M | -19.75M | -35.54M | 12.30M | -28.53M | -27.35M | -20.96M | -11.77M | -14.96M | -12.27M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -2.31M | -19.75M | -35.54M | 24.26M | -28.53M | -27.35M | -20.96M | 9.31M | -14.96M | -12.27M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -2.31M | -19.75M | -35.54M | 24.26M | -28.53M | -27.35M | -20.96M | 9.31M | -14.96M | -12.27M | ||||||
| Income towards Parent CompanyParent Net Inc | -2.31M | -19.75M | -35.54M | 24.26M | -28.53M | -27.35M | -20.96M | 9.31M | -14.96M | -12.27M | ||||||
| Net Income towards Common StockholdersNet Income | -2.31M | -19.75M | -35.54M | 24.26M | -28.53M | -27.35M | -20.96M | 9.31M | -14.96M | -12.27M | ||||||
| Additional items | ||||||||||||||||
| EPS (Basic) | -0.05 | -0.42 | -0.76 | 0.52 | -0.60 | -0.58 | -0.44 | 0.20 | -0.32 | -0.26 | ||||||
| EPS (Diluted) | -0.05 | -0.42 | -0.76 | 0.52 | -0.60 | -0.58 | -0.44 | 0.20 | -0.32 | -0.26 | ||||||
| Shares Outstanding | 23.44M | 25.04M | 27.26M | 29.65M | 32.19M | 37.09M | 43.96M | 46.74M | 47.07M | 46.25M | 47.23M | 47.23M | 47.23M | 47.23M | 47.23M | 47.24M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 32.19M | 37.09M | 43.96M | 46.74M | 47.07M | 46.25M | 47.23M | 47.23M | 47.23M | 47.23M | 47.23M | 47.24M | ||||
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 23.69M | 26.12M | 27.77M | 29.93M | 35.94M | 39.62M | 46.58M | 46.80M | 47.21M | 47.22M | 47.23M | 47.23M | 47.23M | 47.23M | 47.23M | 47.25M |
| EBITDA | -5.58M | -23.39M | -30.00M | -4.35M | -28.41M | -23.96M | -26.24M | -12.46M | -15.74M | -13.87M | ||||||
| Tax Rate | -11.80% | -1.17% | -0.14% | -92.17% | -0.04% | 0.00% | 172.49% | -0.01% |